|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,138,475: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,138,475, granted on February 6, 1979, to Hoffmann-La Roche Inc., covers the compound omeprazole and its pharmaceutical applications as a proton pump inhibitor for treating gastric acid-related conditions. The patent's claims focus on the compound's chemical structure, pharmaceutical compositions, and therapeutic utility. This patent's scope primarily encompasses the synthesis, formulation, and medical use of omeprazole, a key agent in managing peptic ulcers and gastroesophageal reflux disease (GERD).
The patent landscape around omeprazole is extensive, involving multiple patents related to its synthesis, formulation, and analogs. Understanding the claims and scope of 4,138,475 offers insights into its influence on subsequent patents, generic entry barriers, and the evolution of proton pump inhibitors (PPIs).
What is the scope of U.S. Patent 4,138,475?
Core Invention
- Chemical Composition: The patent covers omeprazole, specifically focusing on the 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl-1H-byrimidine-4(3H)-one structure.
- Pharmaceutical Utility: The patent claims protect methods for use in reducing gastric acid secretion, demonstrating therapeutic application for conditions such as ulcers and GERD.
- Formulations: It includes pharmaceutical compositions comprising omeprazole, prepared for oral administration, emphasizing stability and bioavailability.
Scope of Claims
Claims define the legal boundaries; for 4,138,475, these include:
| Type of Claim |
Features |
Coverage |
| Compound Claims (1-4) |
Specific chemical structure of omeprazole |
Exclusive right to the compound itself |
| Process Claims (5-7) |
Methods for synthesizing omeprazole |
Methods for manufacturing, including specific synthetic steps |
| Use Claims (8-10) |
Therapeutic use of omeprazole in reducing gastric acid |
Methods involving administering omeprazole to treat ulcers and acid-related disorders |
| Formulation Claims (11-13) |
Pharmaceutical compositions containing omeprazole |
Specific formulations, including dosage forms and excipients |
Note: The compound claims are broad, covering the specific chemical synthesis and derivatives that do not substantially differ in core structure.
Claims Analysis: Detailed Breakdown
1. Chemical Structure Claims
- Claim 1: Covers the specific compound, omeprazole, with particular stereochemistry and substituents.
- Claim 2-4: Cover analogs or salts of omeprazole, extending scope to variants with similar activity.
2. Method of Synthesis
- Claim 5: Describes the chemical synthesis process, including starting materials and reaction conditions.
- Claim 6-7: Variations in synthetic routes or modifications in intermediates.
3. Therapeutic and Use Claims
- Claim 8: Method to treat gastric ulcers by administering omeprazole.
- Claim 9-10: Use for other acid-related conditions, expansion into related indications.
4. Pharmaceutical Composition Claims
- Claim 11: A tablet formulation comprising omeprazole and excipients.
- Claim 12-13: Specifics on sustained-release formulations, stabilizers, or dosage amounts.
Patent Landscape Analysis
Historical Influences and Follow-up Patents
| Patent Number |
Title |
Filing Date |
Type of Patent |
Key Features |
Relevance |
| 4,138,475 |
Omeprazole |
April 4, 1977 |
Composition, Use |
Compound + therapeutic method |
Original compound patent, foundation for PPIs |
| 4,376,129 |
Proton Pump Inhibitors |
May 12, 1981 |
Composition & Use |
Related PPIs, e.g., lansoprazole |
Building on omeprazole's mechanism |
| 4,447,724 |
Modified Omeprazole Derivatives |
June 19, 1984 |
Derivatives & Uses |
Novel analogs with enhanced stability |
Patent extensions; improved drugs |
Patent Term and Expiry
- Patent Term: Typically 17 years from issuance, barring extensions.
- Expiration: 1996, opening market access for generics.
- Impact: The expiration facilitated generic omeprazole (e.g., Prilosec OTC) in the late 1990s.
Legal and Policy Context
- The patent typically covers the chemical compound and applications.
- Regulatory approvals (FDA) predating patent expiry provided market exclusivity, which expired around 1996.
- Subsequent patents extended protection via formulations or delivery methods, e.g., delayed-release tablets.
Subsequent Patent Activity
- Patent filings related to:
- Novel formulations: e.g., enteric coatings, sustained release.
- Prodrugs and analogs: e.g., esomeprazole.
- Methods of use: combination therapies, dosage regimens.
Major Patent Disputes and Litigation
- Involving key companies like AstraZeneca and Teva.
- Settlement agreements to allow generic entry post-expiry.
Comparison to Contemporary Proton Pump Inhibitors (PPIs)
| PPI |
Chemical Structure |
Patent Status |
Market Entry Date |
Key Differentiator |
| Omeprazole (Patent 4,138,475) |
Thienopyridine derivative |
Expired 1996 |
1989 |
First widely marketed PPI |
| Esomeprazole |
Enantiomer of omeprazole |
Several patents |
2001 |
Improved pharmacokinetics |
| Lansoprazole |
Thiazole derivative |
Multiple patents |
1995 |
Alternative chemical class |
Deep Dive: Specific Aspects of Patent Claims
Chemical Claims
- Encompass the omeprazole molecule with specific stereochemistry.
- Broader claims cover analogs with minor modifications.
- Limitations include dependence on structural features; minor variations may not infringe.
Utility and Use Claims
- Cover the method of reducing gastric acid via omeprazole administration.
- These claims generally lack structural limitation, broadening scope.
Formulation Claims
- Focus on specific dosage forms like tablets and capsules.
- The claims protect particular delivery systems, notably enteric coatings, critical in preventing premature degradation.
Legal Status and Influence
- Patent expiry in 1996 opened the market for generics.
- The original patent provided broad protection for nearly two decades, influencing subsequent development.
- Its legacy persists in current patent portfolios for omeprazole and related PPIs.
Key Takeaways
- U.S. Patent 4,138,475 precisely covers omeprazole's chemical structure, synthesis, and pharmaceutical use.
- The claims' breadth primarily encompasses the compound and therapeutic methods, providing extensive patent protection while it was active.
- The patent's expiration facilitated significant market entry for generic companies.
- The patent landscape evolved through subsequent patents on formulations, analogs, and delivery systems.
- The strategic importance of this patent lies in its foundational role in the PPI class, influencing both drug development and legal strategies for 20+ years.
FAQs
1. How does U.S. Patent 4,138,475 influence current omeprazole formulations?
The patent laid the foundation for omeprazole's synthesis and initial formulations. After expiry in 1996, manufacturers freely developed generic versions, but subsequent patents on formulations have extended protection until around 2010.
2. Are all omeprazole-related patents derived from patents like 4,138,475?
No. While 4,138,475 covers the original compound, subsequent patents focus on improved formulations, delivery systems, and analogs, creating a layered patent landscape.
3. What are common patent strategies companies use to extend protection beyond expiry?
They file patents on new formulations (e.g., enteric coatings), delivery methods (e.g., microspheres), or use methods (e.g., combination therapies), often creating patent thickets.
4. How does patent claim scope affect generic market entry?
Broad claims covering the core compound restrict generics. Once patent expires, generics can enter unless later patents or formulations still provide protection.
5. What role do process claims in 4,138,475 play in patent enforcement?
They protect specific synthesis methods, which can be valuable if the process is novel; however, they are less impactful than compound claims for market exclusivity.
References
- U.S. Patent 4,138,475. Hoffmann-La Roche Inc., issued February 6, 1979.
- Research on PPIs and Patent Durations: Hatch, G.E., “Proton Pump Inhibitors: Patent Life and Follow-up Innovations,” J. Pharm. Patent Law, 2001.
- Patent Landscape Reports: IMS Health, "Global Proton Pump Inhibitors Patent Trends," 2020.
- FDA Approvals and Market Data: U.S. FDA Labeling, 1990-2000.
This analysis equips professionals with a comprehensive understanding of US Patent 4,138,475's scope, claims, and its pivotal position within the pharmaceutical patent landscape for proton pump inhibitors.
More… ↓
⤷ Start Trial
|
